A number of monoclonal antibodies targeting MIF have been developed; BaxB01, BaxG03, and BaxM159 induced apoptosis in prostate cancer cells in-vitro by inhibiting ERK1/2 signaling, leading to reduced tumor growth in a xenograft mouse model (274, 279). Here, MIF is linked to prostate cancer.